Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 1
1983 1
1984 1
1985 2
1987 6
1988 1
1989 9
1990 11
1991 1
1992 4
1993 5
1994 11
1995 12
1996 6
1997 8
1998 5
1999 8
2000 6
2001 10
2002 10
2003 4
2004 10
2005 1
2006 6
2007 10
2008 7
2009 8
2010 10
2011 12
2012 9
2013 7
2014 4
2015 3
2016 4
2017 4
2018 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

213 results
Results by year
Filters applied: . Clear all
Page 1
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. McDermott DF, et al. Among authors: gore me. Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Nat Med. 2018. PMID: 29867230 Free PMC article. Clinical Trial.
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Rini BI, et al. Among authors: gore me. Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Lancet. 2011. PMID: 22056247 Clinical Trial.
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. Motzer RJ, et al. Among authors: gore me. Lancet Oncol. 2013 May;14(6):552-62. doi: 10.1016/S1470-2045(13)70093-7. Epub 2013 Apr 16. Lancet Oncol. 2013. PMID: 23598172 Clinical Trial.
Mucinous ovarian cancer.
Harrison ML, Jameson C, Gore ME. Harrison ML, et al. Among authors: gore me. Int J Gynecol Cancer. 2008 Mar-Apr;18(2):209-14. doi: 10.1111/j.1525-1438.2007.01022.x. Epub 2007 Jul 11. Int J Gynecol Cancer. 2008. PMID: 17624989 Review.
Imaging in metastatic renal cell carcinoma.
Griffin N, Gore ME, Sohaib SA. Griffin N, et al. Among authors: gore me. AJR Am J Roentgenol. 2007 Aug;189(2):360-70. doi: 10.2214/AJR.07.2077. AJR Am J Roentgenol. 2007. PMID: 17646462 Review.
Biological response modifiers in melanoma.
Bridgewater JA, Gore ME. Bridgewater JA, et al. Among authors: gore me. Br Med Bull. 1995 Jul;51(3):656-77. doi: 10.1093/oxfordjournals.bmb.a072985. Br Med Bull. 1995. PMID: 7552087 Review. No abstract available.
The role of human endogenous retroviruses in melanoma.
Singh S, Kaye S, Gore ME, McClure MO, Bunker CB. Singh S, et al. Among authors: gore me. Br J Dermatol. 2009 Dec;161(6):1225-31. doi: 10.1111/j.1365-2133.2009.09415.x. Epub 2009 Jul 20. Br J Dermatol. 2009. PMID: 19785608 Review.
213 results